Overview
Significant advancements in pulmonary arterial hypertension (PAH) therapies have occurred over the past few decades, but managing this progressive condition remains challenging due to its complex pathophysiology and limited treatment options that can reverse vascular remodeling. Many patients eventually develop right ventricular failure underscoring the need for earlier diagnosis and more effective treatments. Novel agents comprising signaling regulators, combination approaches, and cell-based therapies are emerging as promising therapeutics.
Join us for this live program showcasing a cutting-edge educational platform that draws inspiration from the classic game show "Family Feud." Audience attendees will engage in a series of medical knowledge challenges and discussions with topics sourced directly from real-time data using powerful artificial intelligence (AI) capabilities. Agenda topics therefore reflect the most current trends, concerns, and advancements related to the treatment of patients with PAH with a focus on current data related to emerging therapeutic drug classes and associated adverse events. Discussion surrounding what these data mean for practice and strategies to tailor PAH management to improve patient outcomes will be highlighted throughout this highly interactive session.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Outline the issues that affect the quality of life for patients with PAH
- Describe the guideline-based risk stratification criteria used in PAH
- Apply risk stratification tools toward individualizing the management of PAH
- Summarize safety and efficacy data pertaining to current and emerging PAH-specific agents
Rajan Saggar, MD
Co-Director Pulmonary Vascular Disease Program
David Geffen School of Medicine, UCLA
Los Angeles, California
Hilary DuBrock, MD
Pulmonary/Critical Care Specialist
Mayo Clinic
Rochester, MN
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.